LNP platforms
Lipid nanoparticles (LNPs) act as advanced nanocarriers for nucleic acid delivery. They help protect the active payload from systemic degradation and deliver it to the intended site of action. By avoiding degradation and increasing delivery of their payload to the cytosol, LNPs enable more efficient & more effective nucleic acid therapeutics.
Customized LNP (cLNP) development
We believe that customized LNPs are critical enablers in advancing nucleic acid-based products to new levels of prophylactic and therapeutic utility. etherna has built expertise and implemented a suite of experimental approaches to customize LNPs for specific therapeutic applications. Additionally, etherna has advanced proprietary ionizable lipid libraries with different properties that we use to develop cLNPs. Our cLNP development capabilities are evidenced by our innovative and proprietary LNP platforms. We tailored those for specific routes of administration allowing better targeted biodistribution with an improved safety profile. Read below about some examples of cLNPs we have developed. With our expertise, suite of experimental tools, and proprietary ionizable lipid libraries, we support the development of LNPs customized for a specific payload and application.
Cancer vaccines
Intra-tumoral (IT) administration
- Maximized local mRNA expression in tumor
- Reduced off-target expression in liver
- Reduced reactogenicity and inflammation
Immuno-oncology
Intramuscular (IM) administ
- Utilize novel ionizable lipids in proprietary constructs to maximize local mRNA expression
- These formulations also show good tolerability and safety, with very low local reactogenicity
Prophylactic vaccines
Intramuscular (IM) administr
- Utilize novel ionizable lipids in proprietary constructs to maximize local mRNA expression
- These formulations also show good tolerability and safety, with very low local reactogenicity
Auto-immune diseases
- Induction of immune tolerance against auto-antigen
Liver diseases, secreted factors
- High expression in liver after intravenous administration
Comprehensive
Our different families of LNP formulations cover different therapeutic applications, such as prophylactic and cancer vaccines, gene therapy, protein replacement, etc.
Customizable
With our expertise, suite of experimental tools, and proprietary ionizable lipid libraries, we support the development of LNPs customized for a specific payload and application.
World Class facilities
Our world-class LNP manufacturing facilities in Ghent & Niel, Belgium, support the production of LNPs for any preclinical project and scale up the LNP production to a GMP-ready stage.
“I’m very happy to let you know that the FDA informed us that our IND was cleared! We do expect non-hold questions in the next few weeks. We thank you so much for your great contribution!”
Versameb“etherna’s eGFP gives 3x higher expression than all others previously tested”
Karolinska Institute“I am writing to you following the experiments we performed using the GFP mRNA received from eTheRNA….. we found it to be an excellent cargo in-vitro in comparison to others”
Dan Peer“….we have now conducted our investigational experiments and I can confirm that your mRNA performed wonderfully!”
Resolution Tx“…we are very confident on ETheRNA performance. All good so far!”
Scripps“…It has certainly been a very pleasant experience so far…”
Diosynvax“I have very much enjoyed working with the team at eTheRNA. I’ve been impressed with the quality of the work and the responsiveness of the team” – etherna’s mRNA is superior to that of Aldevron
HDT BioContact us with any queries or for pricing information.